Copy to clipboard 
Medacta acquired Parcus Medical from Anika. The transaction is complete, and terms are undisclosed. Parcus, a provider of sports medicine and arthroscopy solutions, posted 2024 revenue of $16 million.
The acquisition will enable Medacta to accelerate its expansion of its sports medicine offering, while also gaining access to additional U.S. sales agents and distributors in over 45 countries.
Parcus will be integrated into Medacta’s Sportsmed business line, and Medacta will take over Parcus’ U.S. manufacturing site in Florida.
Parcus’ portfolio supports surgical procedures in the shoulder, knee, hip and foot & ankle. The acquisition expands and complements Medacta’s sports medicine solution offerings in Sportsmed, which achieved $1.8 million in sales for the first half of 2024 per ORTHOWORLD estimates.
Medacta will be able to leverage Parcus Medical’s brands and innovations to better serve the market. Furthermore, Medacta will be able to capitalize opportunities due to its strong presence in the fast-growing U.S. ASC market.
In 4Q24, Anika announced its plan to divest the Parcus Medical business, which it had acquired in 2020.
Francesco Siccardi, CEO of Medacta, commented: “Parcus Medical is a great addition to Medacta’s Sportsmed business with its complementary product portfolio and trusted brands. The acquisition is in line with our strategy to seize opportunities to further perfect our offerings to sustainably improve patient outcome and patient satisfaction. I warmly welcome all 50 employees to Medacta, all partners, sales agents, distributors and customers.”
Source: Medacta
Medacta acquired Parcus Medical from Anika. The transaction is complete, and terms are undisclosed. Parcus, a provider of sports medicine and arthroscopy solutions, posted 2024 revenue of $16 million.
The acquisition will enable Medacta to accelerate its expansion of its sports medicine offering, while also gaining access to additional U.S....
Medacta acquired Parcus Medical from Anika. The transaction is complete, and terms are undisclosed. Parcus, a provider of sports medicine and arthroscopy solutions, posted 2024 revenue of $16 million.
The acquisition will enable Medacta to accelerate its expansion of its sports medicine offering, while also gaining access to additional U.S. sales agents and distributors in over 45 countries.
Parcus will be integrated into Medacta’s Sportsmed business line, and Medacta will take over Parcus’ U.S. manufacturing site in Florida.
Parcus’ portfolio supports surgical procedures in the shoulder, knee, hip and foot & ankle. The acquisition expands and complements Medacta’s sports medicine solution offerings in Sportsmed, which achieved $1.8 million in sales for the first half of 2024 per ORTHOWORLD estimates.
Medacta will be able to leverage Parcus Medical’s brands and innovations to better serve the market. Furthermore, Medacta will be able to capitalize opportunities due to its strong presence in the fast-growing U.S. ASC market.
In 4Q24, Anika announced its plan to divest the Parcus Medical business, which it had acquired in 2020.
Francesco Siccardi, CEO of Medacta, commented: “Parcus Medical is a great addition to Medacta’s Sportsmed business with its complementary product portfolio and trusted brands. The acquisition is in line with our strategy to seize opportunities to further perfect our offerings to sustainably improve patient outcome and patient satisfaction. I warmly welcome all 50 employees to Medacta, all partners, sales agents, distributors and customers.”
Source: Medacta
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
